Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.35 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.33 |
| ▸ | TLR2 | O60603 | 2/20 | 0.32 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.31 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.31 |
| ▸ | GLP1R | P43220 | 4/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4587689 | 0.94 | FOLH1 (0.38) | FOLH1SIRT5TLR2SIRT6SIRT1 | |
| SCHEMBL4587271 | 0.89 | NOD1 (0.38) | FOLH1SIRT5TLR2SIRT6SIRT1 | |
| SCHEMBL4588703 | 0.88 | FOLH1 (0.37) | FOLH1SIRT5PRMT1 | |
| SCHEMBL4603752 | 0.85 | NOD1 (0.41) | TLR2GLP1R | |
| SCHEMBL4587984 | 0.85 | NOD1 (0.41) | TLR2GLP1R | |
| SCHEMBL4587331 | 0.85 | PTGS1 (0.36) | FOLH1PRMT1 | |
| SCHEMBL4589185 | 0.82 | NOD1 (0.46) | GLP1R | |
| SCHEMBL4587684 | 0.82 | NOD1 (0.46) | GLP1R | |
| SCHEMBL4586378 | 0.81 | FOLH1 (0.39) | FOLH1SIRT5PRMT1 | |
| SCHEMBL4587658 | 0.78 | PTGS1 (0.36) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | NITROMED, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1692107-A4 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1692107-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | Nitromed, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005060603-A2 | NITRIC OXIDE RELEASING PYRUVATE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287407-A1 | Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use | PC, PDK1, NOS3 | FOLH1 2571/4885SIRT5 182/4885PRMT1 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.